Renal Osteodystrophy (CKD Mineral and Bone Disorder)

Renal osteodystrophy is the bone disease that develops in chronic kidney disease. Failing kidneys retain phosphate and stop activating vitamin D, calcium falls, and the parathyroid glands respond by releasing large amounts of parathyroid hormone (PTH), which pulls calcium out of bone.

Today it is seen as part of a wider problem, CKD mineral and bone disorder (CKD-MBD), which also causes calcium to deposit in arteries and heart valves. It begins silently when kidney function falls below roughly half of normal and affects nearly everyone on dialysis to some degree.

Symptoms

• Usually none until advanced
• Bone and joint pain, especially hips, back and legs
• Fractures after minor injuries
• Muscle weakness, particularly climbing stairs
• Persistent itching
• Red eyes or hard lumps under the skin from calcium deposits
• Slow growth and bone deformities in children

Causes and risk factors

Reduced phosphate excretion raises the hormone FGF23 and later blood phosphate; less active vitamin D (calcitriol) is produced; calcium absorption falls. These changes drive secondary hyperparathyroidism and high-turnover bone disease. Over years the parathyroid glands may enlarge and become autonomous (tertiary hyperparathyroidism). The opposite pattern, adynamic low-turnover bone, results from over-suppression of PTH with calcium and vitamin D, and is common in older and diabetic patients. Acidosis, steroids, and in the past aluminium, also weaken bone.

How it is diagnosed

• Calcium, phosphate, PTH and alkaline phosphatase: Monitored every 1 to 6 months depending on the stage of kidney disease; trends guide treatment.
• 25-hydroxy vitamin D: Deficiency is common and corrected first.
• Bone density scan (DXA): Predicts fracture risk but cannot tell the type of bone disease.
• X-rays or CT: May show bone erosion, fractures or vascular calcification.
• Parathyroid ultrasound and sestamibi scan: Locate enlarged glands when surgery is being planned.
• Bone biopsy: The definitive test for bone turnover, used rarely in specialised centres.

Treatment options

• Dietary phosphate control: Less processed food, cola drinks and phosphate additives, guided by a renal dietitian.
• Phosphate binders: Calcium-based, sevelamer, lanthanum or iron-based tablets taken with meals.
• Vitamin D: Native vitamin D for deficiency; active forms such as calcitriol, alfacalcidol or paricalcitol to suppress PTH.
• Calcimimetics: Cinacalcet tablets or intravenous etelcalcetide lower PTH in dialysis patients.
• Adequate dialysis: Longer or more frequent sessions remove more phosphate.
• Parathyroidectomy: Surgical removal of most of the parathyroid tissue when PTH remains very high despite drugs, or with severe symptoms or calciphylaxis.
• Kidney transplantation: Corrects much of the disorder, though hyperparathyroidism may persist.

When it is urgent

Seek urgent local care for a suspected fracture, for very painful purple or black skin patches or ulcers (possible calciphylaxis), or for muscle spasms, tingling and cramps after parathyroid surgery, which indicate a dangerously low calcium.

Travelling to Türkiye for treatment

This is a long-term condition managed by monthly blood tests and adjustment of tablets at your kidney or dialysis unit, so it is not a reason to travel in itself. The exception is parathyroidectomy for severe hyperparathyroidism, which can be planned abroad if you can stay 1 to 2 weeks for calcium monitoring, including dialysis if you need it, and have follow-up arranged at home.

Send your reports, scans and a short history and a Clinic-Y coordinator replies within 24 hours with suitable teams and written, all-inclusive proposals side by side. Reviewing your case is free.

الأسئلة المتكررة